Join Now

Category Archives: BioUtah News

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

By admin | Published February 26, 2024

SALT LAKE CITY, Feb. 26, 2024 (GLOBE NEWSWIRE) — PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II,” or “COVER DFUS II.” COVER DFUS […]

| Comments Off on PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

Utah Legislative Recap: February 23, 2024

By admin | Published February 22, 2024

Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create and […]

| Comments Off on Utah Legislative Recap: February 23, 2024

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

By admin | Published February 22, 2024

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 BillionCatheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated […]

| Comments Off on EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

By Natalie Themm | Published February 22, 2024

SALT LAKE CITY, UT, February 22, 2024 (BusinessWire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development. With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony […]

| Tagged | Comments Off on Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

Nomi Health Announces Advisory Board to Guide Integrated Care Programs, Closing Gaps in Care for Patients Served by Payers and Providers

By Natalie Themm | Published February 22, 2024

Company Introduces Success Care to Tackle Substance Use Disorder Treatment

| Tagged | Comments Off on Nomi Health Announces Advisory Board to Guide Integrated Care Programs, Closing Gaps in Care for Patients Served by Payers and Providers

Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

By Natalie Themm | Published February 22, 2024

Recipients’ research focused on melanoma diagnosis, treatment response in advanced NSCLC, and bypassing common hurdles in NSCLC diagnosis and treatment

| Tagged | Comments Off on Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

Thermo Fisher Scientific Recognized by Customers for Contract Manufacturing Leadership

By Natalie Themm | Published February 22, 2024

Pharma and biotech customers distinguish excellence in capabilities, compatibility, expertise, quality and reliability

| Tagged | Comments Off on Thermo Fisher Scientific Recognized by Customers for Contract Manufacturing Leadership

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

By admin | Published February 15, 2024

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience […]

| Comments Off on Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

By admin | Published February 15, 2024

FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65and $15.35 per Share in the Late Spring or Early […]

| Comments Off on Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

By admin | Published February 15, 2024

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year   OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, […]

| Comments Off on PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

By admin | Published February 15, 2024

The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, […]

| Comments Off on Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

By admin | Published February 15, 2024

New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the […]

| Comments Off on Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

A Special Thanks To Our Legacy and Platinum Elite Members